关于
  • English
  • About
    • About Sirona
    • Management
    • Board of Directors
    • Strategic Advisory Board
    • Our Partners
  • TFChem
    • About TFChem
    • Management
    • Team
    • TFChem Laboratory Capabilities
  • Programs
    • Proprietary Platform Technology
    • Pipeline
    • Diabetes – SGLT2 Inhibitor
    • Skincare – Dark Spot Correction
    • Skincare – Anti-Aging / Anti-Wrinkle
    • Antiviral
  • News
    • Sirona News
    • Events
  • Investors
    • Financial Information
    • Financial Reports
    • Investor & Media Kit
    • Newsletter
  • Contact
  • Careers

News

Sirona Biochem Closes Non-Brokered Private Placement

January 29th, 2010

VANCOUVER, CANADA: Sirona Biochem Corp. (TSX-V: SBM), an emerging biotech company focused on drug development for diabetes and obesity, announced today that it has arranged a non-brokered private placement for total gross proceeds of $215,000

The private placement, which is subject to TSX Venture Exchange approval, consists of up to 2,150,000 units at 10 cents per unit. Each unit will consist of one common share of the company and one transferrable share purchase warrant.

Each warrant is exercisable into an additional common share of the company for a period of two years at a price of $0.20 per share in the first year of the term of the warrant, and at a price of $0.40 per share in the second year of the term of the warrant.

Finders’ fees may be payable in whole, or in part, on the private placement, pursuant to the policies of the TSX Venture Exchange.

Sirona Biochem intends to use the net proceeds from the private placement primarily towards  business development and general working capital.

SIRONA BIOCHEM

Sirona Biochem Corp. is an emerging biotech company dedicated to the discovery and development of novel drug compounds.   The current focus is on treatments for Type II diabetes and obesity.  Sirona Biochem has entered into a license agreement with TFChem, a drug discovery company based in Rouen, France. TFChem brings a unique solution to the severe drawbacks (stability and bioavailability) usually associated with carbohydrate-based drugs and thus allows the full exploitation of their therapeutic potential and the development of a new drugs. SGLT inhibitors are a new and exciting class of compounds which have great promise and potential to treat both diabetes and obesity.

Contacts:
John Dougherty, Corporate Development 604-641-4466.

Mark Senner
President

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Archives

  • About
  • TFChem
  • Programs
  • News
  • Investors
  • Contact

© 2023 Sirona Biochem.

Sirona Biochem Corp
c/o WeWork
595 Burrard St.
Vancouver, B.C., Canada,V7X 1L4

TFCHEM
Voie de l’innovation
Pharma Parc II Chaussée du Vexin
27100 Val de Reuil, France

General inquires: 604.641.4466
Investor inquiries (Momentum PR): 450.332.6939
info@sironabiochem.com

© 2023 Sirona Biochem.

Sirona Biochem Corp
c/o WeWork
595 Burrard St.
Vancouver, B.C., Canada,V7X 1L4

TFCHEM
Voie de l’innovation
Pharma Parc II Chaussée du Vexin
27100 Val de Reuil, France

General inquires: 604.641.4466
Investor inquiries (Momentum PR): 450.332.6939
info@sironabiochem.com

Enter your info below to subscribe to our newsletter:
Loading